Revlimid Cancer Woes Spark FDA Safety Review

Law360, New York (April 11, 2011, 6:31 PM EDT) -- The U.S. Food and Drug Administration said Friday it was conducting a safety review of the blood cancer treatment drug Revlimid, citing studies that found patients who use the drug could face increased risks of developing secondary cancers.

Without issuing any recommendations about the drug as it’s currently administered, the FDA said it was reviewing all available information on Revlimid’s potential to expose patients to types of cancer other than those it’s designed to treat.

“At this time, there is no recommendation to delay, modify or...
To view the full article, register now.